NDAORALTABLET
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
SOTYKTU (deucravacitinib) by Bristol Myers Squibb is tyrosine kinase 2 inhibitors [moa]. First approved in 2022.
Drug data last refreshed 32m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOTYKTU (deucravacitinib) is an oral tyrosine kinase 2 (TYK2) inhibitor approved by the FDA in September 2022 for the treatment of plaque psoriasis. TYK2 inhibition modulates immune signaling pathways involved in inflammatory skin diseases, offering a targeted small-molecule approach to dermatologic inflammation.
$0.034BPart D
Peak16.6 years to LOEEarly in peak cycle with modest Part D penetration; brand team is likely focused on expanding market access and driving prescription volume growth in dermatology.
Mechanism of Action
Tyrosine Kinase 2 Inhibitors
Pharmacologic Class:
Tyrosine Kinase 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Deucravacitinib in the Treatment of Cicatricial Alopecias
Started May 2026
20 enrolled
Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Started Feb 2026
35 enrolled
Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Started Dec 2025
366 enrolled
Plaque Psoriasis
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Started Sep 2025
3,040 enrolled
Plaque Psoriasis
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Started Aug 2025
200 enrolled
Psoriasis
Worked on SOTYKTU at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.